ADVA
20.12.2019 09:02:09 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that its FSP 150-XG480 has become the first 100Gbit/s solution on the market to achieve MEF 3.0 Carrier Ethernet certification. The compact metro edge device is now the industry’s only 100Gbit/s packet aggregation and demarcation technology proven to offer the highest available levels of performance, assurance and agility. With the ADVA FSP 150-XG480, enterprises and communication service providers (CSPs) can address the boom in cloud computing and mobile services by smoothly transitioning to 10 and 25Gbit/s service aggregation. What’s more, ADVA’s MEF 3.0-compliant technology enables them to meet the need for high-capacity wholesale, mobile and business services with a solution that supports automated networking and 5G-ready architectures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191220005017/en/
“CSPs now have the power to tackle the demand for 100Gbit/s aggregation at the metro edge with a solution guaranteed to deliver the highest industry standards for performance and assurance. With our unique technology, there’s now a simple and extremely cost-efficient route to MEF 3.0-certified 100Gbit/s service aggregation,” said James Buchanan, GM, Edge Cloud, ADVA. “Higher speeds in the access network are becoming essential. In fact, with the emergence of more and more connected devices as well as the unprecedented surge in video streaming platforms, 10Gbit/s is becoming the new 1Gbit/s. What our FSP 150-XG480 offers is a future-proof way to deliver MEF CE services up to 100Gbit/s and enable the efficient and reliable aggregation of multiple 10Gbit/s streams.”
The compact and powerful ADVA FSP 150-XG480 aggregator with high-density 1, 10 and 25Gbit/s port count is the ultimate tool for fighting bandwidth bottlenecks and evolving metro networks to 100Gbit/s. Its MEF 3.0-compliant interfaces and operation and management capabilities enable seamless integration into existing networks and established processes. The ADVA FSP 150-XG480 offers a range of advantages for connectivity and synchronization in mobile backhaul networks. These include leveraging ADVA’s Oscilloquartz Syncjack™ technology to constantly control the accuracy of network timing. It’s also the only device available with 100Gbit/s line-rate service activation and testing, so there’s no need for CSPs to compromise on high-value SLA-based business services.
“Achieving MEF 3.0-compliant status with our FSP 150-XG480 highlights the leading role ADVA continues to play in the Carrier Ethernet space. This certification is also great news for enterprises across the world as well as mobile network operators looking to meet soaring data demand. Now they can map 10 and 25GbE into 100Gbit/s aggregated bandwidth with a solution that easily expands to meet the coming requirements of 5G networks,” commented Eli Angel, VP, product line management, Ethernet access, ADVA. “Our FSP 150-XG480 is the key to future scalability. It also features an incredibly small form factor and environmentally hardened design, delivering a significant cost advantage over competing technology.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191220005017/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
